Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 167 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: amantadine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder

NCT00411398
View directory record Official record
Conditions
General Anxiety Disorder, Social Anxiety Disorder
Interventions
Namenda/Memantine
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 4 Interventional Results available

Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression

NCT00305578
View directory record Official record
Conditions
Bipolar Depression
Interventions
Memantine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine

NCT00416962
View directory record Official record
Conditions
Healthy
Interventions
amantadine hydrochloride, oseltamivir phosphate
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Sep 3, 2026, 11:04 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease

NCT01652534
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Amantadine, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 2 Interventional Results available

Memantine Treatment of Compulsive Buying

NCT00830375
View directory record Official record
Conditions
Compulsive Buying
Interventions
Memantine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

NCT00867139
View directory record Official record
Conditions
Influenza
Interventions
TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Sep 3, 2026, 11:04 AM EDT
Withdrawn Phase 2 Interventional

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

NCT06234462
View directory record Official record
Conditions
Long COVID, Post-Acute COVID-19 Syndrome
Interventions
Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling, Medications for symptoms management
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 2 Interventional Results available

Therapy in Amyotrophic Lateral Sclerosis (TAME)

NCT02118727
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia
Interventions
Memantine, Placebo (for Memantine)
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Irvine, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 3 Interventional Results available

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

NCT00566852
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Memantine, Placebo, Whole brain radiation therapy
Drug · Other · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
229
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 183 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 4 Interventional Results available

Memantine for Spasticity in MS Patients

NCT00638027
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
placebo, memantine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 3, 2026, 11:04 AM EDT
Not yet recruiting Phase 2 Interventional

Use of Gocovri to Improve Disability Due to Radiation Encephalopathy

NCT07125222
View directory record Official record
Conditions
Encephalopathy, Radiation Effect
Interventions
Gocovri (extended-release amantidine)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Down Syndrome Memantine Follow-up Study

NCT02304302
View directory record Official record
Conditions
Down Syndrome, Intellectual Disability
Interventions
Memantine, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
15 Years to 32 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 3, 2026, 11:04 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 3, 2026, 11:04 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

NCT04939597
View directory record Official record
Conditions
Central Nervous System Carcinoma
Interventions
Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
137
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 4 Interventional Results available

Brain Aging and Treatment Response in Geriatric Depression

NCT01902004
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Depression
Interventions
Escitalopram, Memantine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 2 Interventional Results available

Amantadine to Speed Awakening After Cardiac Arrest

NCT02486211
View directory record Official record
Conditions
Coma, Heart Arrest, Anoxia
Interventions
Amantadine, Placebo
Drug
Lead sponsor
Jon Rittenberger, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Portland, Maine • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 3 Interventional

Clinical Trial of Memantine for Major Depression

NCT00040261
View directory record Official record
Conditions
Depression
Interventions
Memantine HCL
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 2 Interventional Results available

Memantine Treatment Study of Pathological Gambling

NCT00585169
View directory record Official record
Conditions
Pathological Gambling
Interventions
Memantine Hydrochloride
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Sep 3, 2026, 11:04 AM EDT
Terminated Phase 4 Interventional

Namenda to Prevent Post-Operative Delirium

NCT00303433
View directory record Official record
Conditions
Delirium, Post-Operative States
Interventions
Namenda
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 3, 2026, 11:04 AM EDT
Terminated Not applicable Interventional Results available

Memantine in Adult Autism Spectrum Disorder

NCT01078844
View directory record Official record
Conditions
Autism, Asperger's Disorder, Pervasive Developmental Disorder NOS
Interventions
memantine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 3, 2026, 11:04 AM EDT
Recruiting Phase 2 Interventional

Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)

NCT07248228
View directory record Official record
Conditions
Brain Metastases
Interventions
MA-WBRT (Memory Avoidance Whole Brain Radiation Therapy (MA-WBRT)), HA-WBRT (Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT)), Memantine
Radiation · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 3, 2026, 11:04 AM EDT
Suspended Early Phase 1 Interventional Accepts healthy volunteers

Changes in Glutamatergic Neurotransmission of Severe TBI Patients

NCT04244058
View directory record Official record
Conditions
Disorder of Consciousness, Traumatic Brain Injury
Interventions
Amantadine + L-DOPA, NMDA blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Sep 3, 2026, 11:04 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

NCT01397422
View directory record Official record
Conditions
Dyskinesia, Levodopa Induced Dyskinesia, Parkinson's Disease
Interventions
ADS-5102 (extended release amantadine HCl)
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Sun City, Arizona • Fountain Valley, California • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 3, 2026, 11:04 AM EDT
Terminated Phase 4 Interventional Results available

Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy

NCT04273737
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Amantadine Hydrochloride
Drug
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Sep 3, 2026, 11:04 AM EDT